Navigation Links
Aurigene Highlights its PD-1 peptide, Bet Bromodomain and NAMPT Inhibitors Program at AACR 2013
Date:4/2/2013

BANGALORE, India and BRIDGEWATER, New Jersey, April 2, 2013 /PRNewswire/ --

Aurigene will be presenting poster sessions for three of its programs at the American Associate of Cancer Research (April 6-10 in Washington, DC).

     (Logo: http://photos.prnewswire.com/prnh/20130402/606920)

PD-1 is a 29-amino acid novel peptide (NP-12) that displays sub-nM potency in disruption of PD1-PDL1/L2 interactions. NP-12 is highly effective in antagonizing PD1 signalling, with desirable in vivo exposure upon s.c. dosing. NP-12 inhibits tumor growth and metastasis in preclinical models of cancer and is well tolerated with no overt toxicity at any of the tested doses; currently in IND studies.

Session Title: Equipotent antagonism, transient immune activation and excellent antitumor efficacy with a peptide inhibitor of PD-1 immune check point pathway

ID: Cytokines, Modification of the Tumor Microenvironment, and Intervention - 1231/11 PO.IM02.02.

Date and Time: Mon, Apr 8, 1:00 - 5:00 PM

Bet Bromodomain: Aurigene has identified novel chemical series of lead compounds that show excellent cell based activity. Demonstration of efficacy is on-going.

Session Title: Identification of potent BET bromodomain inhibitors for treatment of cancer

ID: Epigenetic Therapy and Risk Biomarkers 671/1 - PO.MCB06.05.

Date and Time: Sun, Apr 7, 1:00 - 5:00 PM

NAMPT: Aurigene has identified novel chemical series of compounds - lead compounds show excellent cell based activity correlating with biochemical potency, favorable ADME profile, excellent pharmacokinetic profile in mice with good oral bioavailability. The lead compound shows excellent efficacy with tumor regression in pancreatic cancer xenograft mice models. Preclinical studies on-going.

Session Title: Novel inhibitors of nicotinamide phosphoribosyl transferase (NAMPT)

ID: Molecular and Cellular Biology 72

Date and Time: Wednesday Apr 10, 2013 8:00 AM - 12:00 PM

Location: Hall A-C, Poster Section 33

Revised Permanent Abstract Number: 5389

About Aurigene

Aurigene is an India based biotech focussed on small molecule and peptide therapeutics for oncology, inflammation and anti-infectives. Our current pipeline includes several best-in-class and first-in-class assets for oncology and inflammation in preclinical/ IND stage. The most advanced programs include (a) PD-1 peptide therapy for oncology and antibacterial infections; (b) Matriptase - a novel protease for OA currently in preclinical studies; (c) FabI inhibitor in IND studies for MRSA. In addition, Aurigene is building a robust pipeline of early stage assets in emerging areas of cancer metabolism, epigenetics and the TH17 pathway. For more information, please visit the company's website at http://www.aurigene.com.

Media Contact:
Rajshree KT
Head Strategic Alliances
+91-40-4465-7777


'/>"/>
SOURCE Aurigene
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Foremost Expert on Morgellons Disease Highlights the Gravity of This Illness
2. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
3. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
4. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
5. CMC Biologics Highlights Technical Acumen at Upcoming Conferences
6. Journal of Renewable and Sustainable Energy highlights energy trends in China
7. Enterologics Highlights Growing News on Probiotics on the Web
8. Recently Published Economic Analysis Highlights the Financial Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) in the United States (US)
9. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
10. Advanced manufacturing venture highlights regions economic prospects
11. Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Participants of this ... high-performance fume hood. Along with the advantages and disadvantages of ductless, filtered fume ... hoods in the laboratory. , Attendees will learn from an industry expert about ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... biological outbreak is about to be eliminated, said Lyle Probst, President, CEO and ... FireflyDX™ technologies different than other pathogen detection solutions, Probst said, “Sample preparation ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... Department of Financial Services (NYS DFS) cybersecurity regulations have transitioned into ... and insurance organizations operating in the state (“Covered Entities”) to conduct an ...
(Date:9/18/2017)... MONTREAL , Sept. 18, 2017   Montrium , a ... announced an exciting new partnership with a groundbreaking non-profit research organization, ... ... for MDMA-assisted psychotherapy studies for PTSD ... FDA has recently granted Breakthrough Therapy Designation to MDMA for the ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):